Compare DFH & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFH | SDGR |
|---|---|---|
| Founded | 2008 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2020 | 2020 |
| Metric | DFH | SDGR |
|---|---|---|
| Price | $15.22 | $18.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $26.00 | $21.00 |
| AVG Volume (30 Days) | 651.4K | ★ 1.1M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $4,322,848,000.00 | $255,869,000.00 |
| Revenue This Year | $0.81 | $0.76 |
| Revenue Next Year | $7.82 | $4.60 |
| P/E Ratio | $40.11 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $12.20 | $10.95 |
| 52 Week High | $31.10 | $23.02 |
| Indicator | DFH | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 70.19 |
| Support Level | N/A | $17.26 |
| Resistance Level | N/A | $19.51 |
| Average True Range (ATR) | 0.00 | 0.72 |
| MACD | 0.00 | 0.28 |
| Stochastic Oscillator | 0.00 | 80.55 |
Dream Finders Homes Inc designs, builds and sells homes in markets throughout the United States. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the maximum of its revenue from the Midwest segment.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.